Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Web – sheet or filament bases; compositions of bandages; or...
Reexamination Certificate
2007-09-11
2007-09-11
Ghali, Isis (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Web, sheet or filament bases; compositions of bandages; or...
C424S443000, C424S448000
Reexamination Certificate
active
10831416
ABSTRACT:
A transdermal delivery system (TDS)for use in treatment of living bodies may be applied as an open (liquid, gel) or closed (patch) article. The TDS is composed of a particular active agent which dictates an associated selection of certain solvents, solvent modifiers, solute modifiers and skin stabilizers with which the medicament forms a true solution that rapidly crosses the skin barrier. The associated selection of the particular solvents, solvent modifiers, solute modifiers and skin stabilizers is based on a balancing of the molecular properties of all the components against the molecular properties of all the components plus the particular active agent. The TDS may also include a source of cellular energy to induce CAMP or cGMP. The TDS improves delivery of active agents having a molecular weight greater than 340 Daltons and increases dosage above 0.25 mg/day for such active agents.
REFERENCES:
patent: 3731683 (1973-05-01), Zaffaroni
patent: 3996934 (1976-12-01), Zaffaroni
patent: 4002775 (1977-01-01), Kabara et al.
patent: 4330551 (1982-05-01), Stout et al.
patent: 4746515 (1988-05-01), Cheng et al.
patent: 4764379 (1988-08-01), Sanders et al.
patent: 4777047 (1988-10-01), Bauer et al.
patent: 4788062 (1988-11-01), Gale et al.
patent: 4789547 (1988-12-01), Song et al.
patent: 4820720 (1989-04-01), Sanders et al.
patent: 4844901 (1989-07-01), Keplinger et al.
patent: 4855294 (1989-08-01), Patel et al.
patent: 4879275 (1989-11-01), Minaskanian et al.
patent: 5053222 (1991-10-01), Takasu et al.
patent: 5077284 (1991-12-01), Loria et al.
patent: 5096715 (1992-03-01), Sinclair
patent: 5164416 (1992-11-01), Nagai et al.
patent: 5230897 (1993-07-01), Griffin et al.
patent: 5240932 (1993-08-01), Morimoto et al.
patent: 5324521 (1994-06-01), Gertner et al.
patent: 5332577 (1994-07-01), Gertner et al.
patent: 5362479 (1994-11-01), Breitzke et al.
patent: 5460821 (1995-10-01), Masiz
patent: 5523090 (1996-06-01), Znaiden et al.
patent: 5529769 (1996-06-01), Cho et al.
patent: 5562910 (1996-10-01), Daynes et al.
patent: 5653970 (1997-08-01), Vermeer
patent: 6019997 (2000-02-01), Scholz et al.
Dasarthy, et al., J. Cellular Physiology, 1991, 148(2) :327-335, Abstract ( Database EBMASE in STN, AN 91290543).
T.K. Ghosh, et al., Methods of Enhancement of Transdermal Drug Delivery, Parts I, IIa & IIb, Chemical Permeation Enhancers, Pharm. Tech. 17 (3):72-98M, 17 (4) :62-89m and 17(5):68-76 (1993).
Crouch, James E., Functional Human Anatomy, Lea & Fibiger, LOCCN 65-12968, Chapter 6, pp. 88-97, 1965.
K. Tojo, Random Brick Model for Drug Transport Across Stratum Corneum, J. Pharm. Sci., 76:889-891, 1987.
S.D. Roy, Preformulation Asptects of Transdermal Delivery Systems, Interpharm Press, Inc., Buffalo Grove, IL 1997.
K. Gjesdal, et al., Transdermal Nitrate Therapy . . . , Brit, J. Clin. Pharmacol. 31:560-562 (1991).
K. Tojo, The Prediction of Transdermal Permeation . . . ,Interpharm Press, Buffalo Grove, IL, 1997.
I. Diez, et al., A Comparative in Vitro Study of Transdermal Absorption . . . , J. Pharm. Sci. 80:931-934 (1991).
W.R., Pfister, et al., Permeation Enhancer Compatible with Transdermal . . . , Pharm. Tech. 14(9):132-140, 14(10):56-60, 1990.
C.D. Vaughn, Using Solubility Parameters in Cosmetic Formulations, J. Soc. Cormet. Chem. 36:319-333 (1985).
J.W. Streilein, In: Immune Mechanisms in Cutaneous Diseases, Ed. D.A. Norris, Marcel Dekker, Inc., New York, pp. 73-96 (1989).
J. Ademola, et al., Safety Assessment of Transdermal and Topical Dermatological Products In: Transdermal and Topical Drug Delivery Systems, Imterpharm Press, Inc., Buffalo Grove, IL (1997).
P. Liu, et al., Quantitative Evaluation of Ethanol Effects on Diffusion . . . , Pharm. Res. 8:865-872 (1991).
Lubert Stryer, Biochemistry, 2nd Edition, Chapter 35, pp. 839-858, W.H. Freeman, Co., Newy York, (1981).
Kenneth B. Seamon, et al., Forskolin: Unique Diterpene Activator of Adenylate Cyclase . . . , PNAS vol. 78, No. 6 pp. 3363-3367 (Jun. 1981).
Hermann P.T. Ammon, et al., Forskolin: from Ayurvedic Remedy to a Moder Agent; Planta Medica, pp. 473-476 (1985).
World Class Help from Rain Forest Herb . . . Cat's Claw, ACCM, vol. II, No. 2, Mar. 1996.
W. Kreutner, et al., Eur. J. of Pharmacology, 1985, 111: 1-8.
G. Marone, et al., Agents and Actions, 1986, 18:96-99.
N.J. De Souza, et al., Medicinal Research, Reviews, 1983, 3:201-219.
K.C. Agarawal, et al., Int. J. Cancer, 1983, 32:801-804.
J. Caprioli, et al., The Lancet, Apr. 30, 1983, pp. 958-960.
E. Linder, et al., Hoechest Aktiengesellschaft, Frankfurt/Main (Germany) Positive Inotropic and Blood Pressure Lowering Activity, 1978.
M.P. Dubey, et al., J. Of Ethnopharmacology, 1981, 3:1-13.
H.W. Hadley, et al., Alt. Med. Re., 1998, 3:361-366.
R.O. Potts, et al., J. Drug Target, 1995, 3:247-251 (Abstract).
P. Xu, et al., Crit. Rev. Ther. Drug Carrier Syst., 1991, 8:211-236 (Abstract).
Kirby Kenneth B
Pettersson Berno
Ghali Isis
McHale & Slavin P.A.
Transdermal Technologies, Inc.
LandOfFree
Compositions for rapid and non-irritating transdermal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for rapid and non-irritating transdermal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for rapid and non-irritating transdermal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3785811